Teva Pharmaceutical Facing EU Antitrust Investigation Over Patent Strategy for MS Drug
shot by IP News Shots / 6:15 pm on 05 March, 2021
The European Commission has launched a formal investigation to evaluate whether Teva Pharmaceutical Industries Ltd. has misused the dominant market position of its branded version of glatiramer acetate violating the bloc’s competition laws. The commission also added that European enforcers will focus on accusations that Teva misused the patent process while also using a communications campaign to obstruct its rivals.
Read more at: https://www.law360.com/articles/1361294/teva-faces-eu-antitrust-probe-over-ms-drug-patent-strategy
Industry: Pharmaceuticals | Type of IP: Litigations